Fiche du document
2014
- doi: 10.5732/cjc.013.10215
- issn: 1944-446X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.5732/cjc.013.10215
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/24384235
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1000-467X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B5189D699B875
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Radiation therapy Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
R.O. Mirimanoff, « High-grade gliomas: reality and hopes. », Serveur académique Lausannois, ID : 10.5732/cjc.013.10215
Métriques
Partage / Export
Résumé
In this issue of the Chinese Journal of Cancer, European experts review current standards, trends, and future prospects in the difficult domain of high-grade glioma. In all fields covered by the different authors, the progress has been impressive. For example, discoveries at the molecular level have already impacted imaging, surgery, radiotherapy, and systemic therapies, and they are expected to play an increasing role in the management of these cancers. The European Organization for Research and Treatment of Cancer (EORTC) has pioneered new treatment strategies and contributed to new standards. The articles in this issue will cover basic molecular biological principles applicable today, novel surgical approaches, innovations in radiotherapy planning and delivery, evidence-based standards for radiotherapy alone or combined with chemotherapy, current standards and novel approaches for systemic treatments, and the important but often neglected field of health-related quality of life. Despite the advances described in these articles, the overall prognosis of high-grade glioma, especially glioblastoma, remains poor, and more research is needed to address this problem.